BioNeex Interviews
Preclinical Stage
Interview with the Founder and President of AptamiR Therapeutics, Dr. Marc Thibonnier
Fri Feb 17 2023 04:43:30 GMT+0000 (Coordinated Universal Time)
AptamiR Therapeutics is a US based preclinical-stage biotech company developing new therapies that target fat accumulation, inflammation, and necrosis to cure related cardiometabolic disorders (obesity, dyslipidemia, diabetes, and metabolic dysfunction-associated fatty liver disease), without altering brain functions, but improving patients’ quality of life.
AptamiR uses the concept of One Drug-Multiple Targets to develop microRNA targeting oligonucleotide therapeutics (ONTs) which simultaneously modulate several target genes in complex diseases.
Tags and Keywords
